In conclusion, our study uncovers a novel role for CYP19A1 in regulating chemoresistance in CRC through modulation of mitochondrial function and complex I activity, and identifies the CYP19A1/estrogen/complex I axis as a potential therapeutic target. This evidence concerns the gene CYP19A1 and colorectal carcinoma.